Mynzepli (Aflibercept)

Aflibercept, the active ingredient in Mynzepli, is a VEGF inhibitor presented as an intravitreal solution for intravitreal use. It treats neovascular age‑related macular degeneration, diabetic macular edema and macular edema secondary to retinal vein occlusion in adult patients. It is indicated for adult patients with these retinal vascular diseases and is administered by a qualified ophthalmologist under sterile conditions.

GNH USA supplies Mynzepli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable cold‑chain logistics and regulatory support for ophthalmic biologics.

Mynzepli, an anti‑VEGF agent, is used to manage retinal diseases driven by abnormal vascular growth.

Neovascular age‑related macular degeneration: reduces sub‑retinal fluid, limits lesion growth and can stabilize or improve visual acuity in affected eyes. Diabetic macular edema: diminishes macular thickening, lowers retinal edema and may lead to measurable gains in visual acuity for patients with diabetes‑related swelling. Macular edema secondary to retinal vein occlusion: lessens fluid accumulation, curtails edema and supports recovery of visual function after occlusive events.

Intravitreal administration of Aflibercept can be associated with ocular and systemic adverse reactions.

Common Side Effects: - Conjunctival hemorrhage: minor bleeding on the eye surface. - Transient increase in intraocular pressure: short‑term rise after injection. - Mild ocular discomfort: temporary irritation or pain.

Serious or Rare Side Effects: - Endophthalmitis: severe intraocular infection requiring urgent treatment. - Retinal detachment: separation of the retina that may need surgery. - Severe intraocular inflammation: marked uveitis or vitritis.

Prior to injection, clinicians should observe specific safety measures.

Patient selection: assess for active ocular infection before injection. Intraocular pressure monitoring: measure IOP before and after the procedure. Anticoagulant therapy: evaluate bleeding risk in patients on systemic anticoagulants. Systemic vascular disease: use caution in patients with recent cardiovascular events. Pregnancy and lactation: avoid use due to unknown safety; discuss risks with physician. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Aflibercept may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent intraocular corticosteroids: may increase risk of intraocular pressure spikes. - Systemic VEGF inhibitors (e.g., bevacizumab, ranibizumab): additive anti‑angiogenic effect could heighten cardiovascular risk.

Moderate Interactions (Monitor Closely): - Anticoagulants or antiplatelet agents: monitor for ocular hemorrhage. - Systemic hypertension medications: watch blood pressure changes post‑injection. - Other intravitreal agents administered within 4 weeks: assess cumulative ocular toxicity.